UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 162

Sortiert nach

The diagnostic accuracies of the 2012 SLICC criteria and the proposed EULAR/ACR criteria for systemic lupus erythematosus classification are comparable

Lupus, 2019-05, Vol.28 (6), p.778-782

2019

Link zum Volltext

Verfügbarkeit prüfen

Comment on 'Systemic autoimmunity with Castleman-like lymphadenopathy: a diagnostic and therapeutic challenge': reply

Scandinavian journal of rheumatology, 2022-05, Vol.51 (3), p.250-251

2022

Link zum Volltext

Verfügbarkeit prüfen

Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases

Lupus, 2017-10, Vol.26 (12), p.1333-1338

2017

Link zum Volltext

Verfügbarkeit prüfen

A rare case of idiopathic multicentric Castleman disease in a patient with long-standing systemic autoimmunity

Scandinavian journal of rheumatology, 2022-03, Vol.51 (2), p.161-163

2022

Link zum Volltext

Verfügbarkeit prüfen

Autoantibodies associated with primary biliary cholangitis are common among patients with systemic lupus erythematosus even in the absence of elevated liver enzymes

Clinical and experimental immunology, 2021-01, Vol.203 (1), p.22-31

2021

Link zum Volltext

Verfügbarkeit prüfen

PO.6.119 Low-dose belimumab and antimalarial agents prevent renal flares in systemic lupus erythematosus: results from four randomised clinical trials

Lupus science & medicine, 2022-10, Vol.9 (Suppl 2), p.A91-A92

2022

Link zum Volltext

Verfügbarkeit prüfen

PO.6.128 Factors associated with survival and discontinuation of antimalarial agents in systemic lupus erythematosus: results from a swedish longitudinal registry

Lupus science & medicine, 2022-10, Vol.9 (Suppl 2), p.A97-A98

2022

Link zum Volltext

Verfügbarkeit prüfen

PO.7.147 Obesity and tobacco smoking are independently associated with poor patient-reported outcomes in patients with systemic lupus erythematosus from a Swedish tertiary referral centre

Lupus science & medicine, 2022-10, Vol.9 (Suppl 2), p.A109-A110

2022

Link zum Volltext

Verfügbarkeit prüfen

Belimumab may not prevent lupus nephritis in serologically active patients with ongoing non-renal disease activity

Scandinavian journal of rheumatology, 2014-10, Vol.43 (5), p.428-430

2014

Link zum Volltext

Verfügbarkeit prüfen

Interferon‐α coincides with suppressed levels of pentraxin‐3 (PTX3) in systemic lupus erythematosus and regulates leucocyte PTX3 in vitro

Clinical and experimental immunology, 2017-07, Vol.189 (1), p.83-91

2017

Link zum Volltext

Verfügbarkeit prüfen

PO.7.159 Objective measures of health-related quality of life may not adequately reflect diseaseburden in systemic lupus erythematosus

Lupus science & medicine, 2022-10, Vol.9 (Suppl 2), p.A116-A117

2022

Link zum Volltext

Verfügbarkeit prüfen

The majority of Swedish systemic lupus erythematosus patients are still affected by irreversible organ impairment: factors related to damage accrual in two regional cohorts

Lupus, 2019-09, Vol.28 (10), p.1261-1272

2019

Link zum Volltext

Verfügbarkeit prüfen

Clinically suspected recurrence of gastric carcinoid proved to be hypocomplementaemic urticarial vasculitis syndrome with pulmonary involvement

Scandinavian journal of rheumatology, 2015-07, Vol.44 (4), p.337-339

2015

Link zum Volltext

Verfügbarkeit prüfen

PO.5.110 Plasma levels of osteopontin in SLE

Lupus science & medicine, 2022-10, Vol.9 (Suppl 2), p.A85-A86

2022

Link zum Volltext

Verfügbarkeit prüfen

De novo renal flares in SLE patients treated for active extra renal disease within five phase Ill clinical trials of belimumab: Implications for revisiting belimumab dose

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2023, Vol.52 (Suppl. 131), p.46

2023

Link zum Volltext

Verfügbarkeit prüfen

OP0189 Rate of Cervical Neoplasia in Systemic Lupus Erythematosus: A Nationwide Cohort-Study

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.128

2016

Link zum Volltext

Verfügbarkeit prüfen

Altered glycan accessibility on native immunoglobulin G complexes in early rheumatoid arthritis and its changes during therapy

Clinical and experimental immunology, 2017-09, Vol.189 (3), p.372-382

2017

Link zum Volltext

Verfügbarkeit prüfen

Longitudinal anti‐nuclear antibody (ANA) seroconversion in systemic lupus erythematosus: a prospective study of Swedish cases with recent‐onset disease

Clinical and experimental immunology, 2020-03, Vol.199 (3), p.245-254

2020

Link zum Volltext

Verfügbarkeit prüfen

PO.2.45 Autoantibodies associated with systemic sclerosis (SSC) in three diseases characterized by type I interferons: a comparison between SLE, primary Sjögren’s syndrome, SSC and healthy blood donors

Lupus science & medicine, 2022-10, Vol.9 (Suppl 2), p.A48-A49

2022

Link zum Volltext

Verfügbarkeit prüfen

S06.1 B cell kinetics upon therapy commencement for active extra-renal systemic lupus erythematosus in relation to development of renal flares

Lupus science & medicine, 2022-10, Vol.9 (Suppl 2), p.A9-A10

2022

Link zum Volltext

Verfügbarkeit prüfen

PO.7.162 Epidemiology of systemic lupus erythematosus in central Sweden: a population-based cohort study from the östergötland county over 14 years

Lupus science & medicine, 2022-10, Vol.9 (Suppl 2), p.A118-A119

2022

Link zum Volltext

Verfügbarkeit prüfen

AB0697 Self-reported health and organ damage predict activity limitations in patients with systemic lupus erythematosus

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.678-678

2013

Link zum Volltext

Verfügbarkeit prüfen

Individual variations in treatment decisions by Swedish rheumatologists regarding biological drugs for rheumatoid arthritis

Scandinavian journal of rheumatology, 2015, Vol.44 (4), p.265-270

2015

Link zum Volltext

Verfügbarkeit prüfen

No evidence of pathogenic involvement of cathelicidins in patient cohorts and mouse models of lupus and arthritis

PloS one, 2014-12, Vol.9 (12), p.e115474

2014

Link zum Volltext

Verfügbarkeit prüfen

Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden

Rheumatology (Oxford, England), 2022-08, Vol.61 (9), p.3596-3605

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 162

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(155)
Mit Volltextzugriff
(129)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

The diagnostic accuracies of the 2012 SLICC criteria and the proposed EULAR/ACR criteria for systemic lupus erythematosus classification are comparable

Comment on 'Systemic autoimmunity with Castleman-like lymphadenopathy: a diagnostic and therapeutic challenge': reply

Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases

A rare case of idiopathic multicentric Castleman disease in a patient with long-standing systemic autoimmunity

Autoantibodies associated with primary biliary cholangitis are common among patients with systemic lupus erythematosus even in the absence of elevated liver enzymes

PO.6.119 Low-dose belimumab and antimalarial agents prevent renal flares in systemic lupus erythematosus: results from four randomised clinical trials

PO.6.128 Factors associated with survival and discontinuation of antimalarial agents in systemic lupus erythematosus: results from a swedish longitudinal registry

PO.7.147 Obesity and tobacco smoking are independently associated with poor patient-reported outcomes in patients with systemic lupus erythematosus from a Swedish tertiary referral centre

Belimumab may not prevent lupus nephritis in serologically active patients with ongoing non-renal disease activity

Interferon‐α coincides with suppressed levels of pentraxin‐3 (PTX3) in systemic lupus erythematosus and regulates leucocyte PTX3 in vitro

PO.7.159 Objective measures of health-related quality of life may not adequately reflect diseaseburden in systemic lupus erythematosus

The majority of Swedish systemic lupus erythematosus patients are still affected by irreversible organ impairment: factors related to damage accrual in two regional cohorts

Clinically suspected recurrence of gastric carcinoid proved to be hypocomplementaemic urticarial vasculitis syndrome with pulmonary involvement

PO.5.110 Plasma levels of osteopontin in SLE

De novo renal flares in SLE patients treated for active extra renal disease within five phase Ill clinical trials of belimumab: Implications for revisiting belimumab dose

OP0189 Rate of Cervical Neoplasia in Systemic Lupus Erythematosus: A Nationwide Cohort-Study

Altered glycan accessibility on native immunoglobulin G complexes in early rheumatoid arthritis and its changes during therapy

Longitudinal anti‐nuclear antibody (ANA) seroconversion in systemic lupus erythematosus: a prospective study of Swedish cases with recent‐onset disease

PO.2.45 Autoantibodies associated with systemic sclerosis (SSC) in three diseases characterized by type I interferons: a comparison between SLE, primary Sjögren’s syndrome, SSC and healthy blood donors

S06.1 B cell kinetics upon therapy commencement for active extra-renal systemic lupus erythematosus in relation to development of renal flares

PO.7.162 Epidemiology of systemic lupus erythematosus in central Sweden: a population-based cohort study from the östergötland county over 14 years

AB0697 Self-reported health and organ damage predict activity limitations in patients with systemic lupus erythematosus

Individual variations in treatment decisions by Swedish rheumatologists regarding biological drugs for rheumatoid arthritis

No evidence of pathogenic involvement of cathelicidins in patient cohorts and mouse models of lupus and arthritis

Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden

Suchergebnisse filtern